TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: HBsAg Seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Peripheral venous CD34 at admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma PTH(1-34) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum albumin-adjusted total calcium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Leisure Activities Questionnaire Activities Sum
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: early recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Overall sum-score of the slit lamp examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Maximum fat oxidation (exercise)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neuropsychological test performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants With Adverse Events and Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Response Rate (ORR) Determined by Investigators Based on RECIST Version 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Seroprotected Subjects Against PRP Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean change in total score on knowledge test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Posttraumatic Stress Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in percent atheroma volume (PAV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma Adenovirus Viremia (Log10 Copies/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Functional autonomy measure (SMAF)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Unplanned hospital readmissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Clinician-Administered PTSD Scale (CAPS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Physical Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time Line Follow Back (TLFB)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Clinical Laboratory Measures: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Suicidal Ideation and Behavior as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of Dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Averaged reduction of negative symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall probability of prodromal Parkinson's disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the maximum 6-minute walk distance (6MGT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of procalcitonin elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of ≥80% Study Area Repigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AGE-RAGE Measurement in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days Remaining in independent living environment
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Clinical Pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: brain activity in the anterior cingulate cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Absolute bioavailability of SRT2104 250 mg suspension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intravenous pharmacokinetics of SRT2104
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thromboxan/prostacyclin balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: steady glucose metabolism in the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Alpha oscillatory power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Directed, long-range cortico-cortical connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hypoglycemic Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with dose limiting adverse events (DLAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Scavenging efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in persistent cognitive impairments
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Endoscopic remission rate of EE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Recovery 40
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in the Outcome Questionnaire 45
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of orthodontic tooth movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Six Minute Walk Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: non-relapse mortality
Endpoint domain: Mortality/survival
Primary endpoint: Maximum tolerated dose based on acute dose-limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients With Optimal Surgical Space Conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Prevention of Aspiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Health Anxiety Inventory (HAI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 6 minute walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of unplanned emergency department (ED) visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Rate of unplanned hospital admissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Baseline level of DNA modifications in White blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Contraction strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contraction pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulse Oximetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Freedom from early death
Endpoint domain: Mortality/survival
Primary endpoint: Maximum Tolerable Dose (MTD) of Pazopanib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temperature of Kaposi's Sarcoma Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temperature in Normal Skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Hemoglobin A1C (HbA1C) at Week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Who Experienced an Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Discontinued Study Medication Due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Joint Erosion Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pain, sedation, nausea & vomiting scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sitting diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With Clinical Objective Response (cOR) in the Breast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Median Training Time to Reach Minimal Passing Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mammographic Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease symptom intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scaffold apposition ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of buprenorphine and its metabolites in plasma and urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart rate monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number (%) of patients with adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number (%) of patients with infusion related AE
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Adult OPD Clients Tested for HIV
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of Sexual Partners Tested for HIV
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Metabolic diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HMGB1 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day procedure-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: 30-day symptomatic re-hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: 30-day brain infections
Endpoint domain: Adverse events/effects
Primary endpoint: serum cytokine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Who Experienced One or More Dose-limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Terminal Half-life (t1/2) of Dalotuzumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Time-concentration Curve From 0 to Infinity Hours (AUC0-∞) of Dalotuzumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profile of prucalopride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Radiological pattern of initial presentation, disease progress, healing and recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Survey of co-morbid lung diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Magnitude of heart rate variability (HRV) decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Viral load response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Evaluation (oSCORAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Evaluation (EASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Evaluation (IGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-Orientated Outcome Measure (POEM)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Success of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's perceptions of pain-discomfort experience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: microRNA-107 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: beta-amyloid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bacterial Count of Streptococcus Mutans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent of tele-visits with a clinical visit match-score of ≥13/15 points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptable safety
Endpoint domain: Adverse events/effects
Primary endpoint: Hemolysis measured by LDH area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Intact Parathyroid Hormone Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Calcium - Phosphorus Product Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quality of Life measured of individuals: SF-36 Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clinical laboratory assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of investigator-rated scores for eyelid margin erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Cardiac output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Geometric Mean Concentration for Serotype 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Concentration for Serotype 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Concentration for Serotype 6B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Concentration for Serotype 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Concentration for Serotype 9V
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Who Died
Endpoint domain: Mortality/survival
Primary endpoint: Muscle spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Capacity Assessments
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cmax (maximum concentration) of JTZ-951
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tmax (time to reach maximum concentration) of JTZ-951
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (area under the concentration-time curve) of JTZ-951
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2 (elimination half-life) of JTZ-951
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pneumonia severity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic statistics of MDCT in obstructive jaundice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants referred to cancer genetic counseling
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants who complete cancer genetic counseling
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change From Baseline in A1C at Week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Who Discontinued Study Treatment Due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Abnormal Electrocardiograms (ECGs) Reported as TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in urinary flow rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Restoration of voiding for women in complete urinary retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Adapted Pittsburgh Sleep Quality Index (PSQI)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: WHO-5
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Satisfaction with Life Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Regain of mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of pulmonary artery pressure (PAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac-rehabilitation attendance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hamilton Depression Rating Scale, 24 Items (HDRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Skin barrier biophysical properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Aborted cardiac arrest
Endpoint domain: Mortality/survival
Primary endpoint: Documented appropriate ICD therapy for ventricular tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Documented appropriate ICD therapy for ventricular fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Achieving a Psoriasis Area Sensitivity Index 75% (PASI-75) Response at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a Physician's Global Assessment (PGA) Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Experiencing an Adverse Event (AE) Up to Week 12
Endpoint domain: Adverse events/effects
Primary endpoint: Satisfaction With HIV Testing Experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of subjects with normal intestinal permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in HIV transcription measured as cell associated HIV-1 RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HIV production measured as plasma HIV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HIV-1 reservoir size measured in PBMCs by Total HIV-1 DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in global clinician abdominal perception scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in global patient abdominal perception scale score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in abdominal circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safe Sleep Environment of Infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep Duration
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Clinical Benefit of Cetuximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain During IUD Insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of active HBV infection in new-born at 6 months of life
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Heart rate accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart rate precision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Respiratory rate accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Respiratory rate precision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Body orientation (position)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-Emergent Treatment Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment-emergent Treatment-related Grade 3 or 4 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Keyboard tapping test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Subclavian Flow to Normal Flow Pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Vertebral Flow to Normal Flow Pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Endothelial Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Oxidative Stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device localization over corneal incision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic criteria adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Treatment Related Adverse Events (TRAEs) Not Expected From Japanese Package Insert
Endpoint domain: Adverse events/effects